ArticleiScience2026
Global and Asian regional burden of musculoskeletal disorders from 1990 to 2023.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using the latest Global Burden of Disease (GBD) 2023 data, this study evaluates the musculoskeletal (MSK) burden across 47 Asian countries by integrating epidemiological metrics, modeled healthcare expenditure, and risk factor attribution. In 2023, MSK disorders accounted for 372 million incident cases globally. Asia served as the primary driver, reaching 203 million incident cases, 999 million prevalent cases, and 91.6 million years lived with disability (YLDs). Low back pain dominated incidence (142 million), whereas osteoarthritis led prevalence (369 million). Modeled expenditure projections indicate that Asia's direct MSK healthcare costs reached approximately $419.6 billion, accounting for 55.9% of the global modeled total ($751.2 billion). High body mass index (BMI) emerged as the fastest-growing modifiable risk factor, with attributable YLDs expanding most markedly in developing economies like India (301%). These findings underscore the need for targeted weight management and early-stage geriatric resource allocations to mitigate Asia's escalating MSK burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.